Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide, a type II topoisomerase inhibitor.

Wei-Qing Li, Hong-Yu Yu, Yi-Ming Li, Xiang Wang, Jin He, Hong-Zhu Yan, Dao-Hua Yang, Xiao-Jun Wu, Li-Jun Hou, Hui-Min Liu, Chun-Yan Xia, Yi-Cheng Lu

Index: Biochem. Biophys. Res. Commun. 446(4) , 1261-7, (2014)

Full Text: HTML

Abstract

Previous studies from this laboratory indicated that microRNA-21 (miR-21) contributes to chemoresistance of glioblastoma multiforme (GBM) cells to teniposide, a type II topoisomerase inhibitor. We also showed that LRRFIP1 is a target of miR-21. In this study, we found that higher baseline LRRFIP1 expression in human GBM tissue (n=60) is associated with better prognosis upon later treatment with teniposide. Experiments in cultured U373MG cells showed enhanced toxicity of teniposide against U373MG cells transfected with a vector that resulted in LRRFIP1 overexpression (vs. cells transfected with control vector). Experiments in nude mice demonstrated better response of LRRFIP1 overexpressing xenografts to teniposide. These findings indicate that high baseline LRRFIP1 expression in GBM is associated with better response to teniposide, and encourage exploring LRRFIP1 as a target for GBM treatment. Copyright © 2014 Elsevier Inc. All rights reserved.